TrialClinical pharmacology in drug development2021

Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers.

Tadakatsu Nakamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.